Savona, Italy

Marco Feligioni


 

Average Co-Inventor Count = 2.0

ph-index = 1


Company Filing History:

goldMedal2 out of 832,812 
Other
 patents

Years Active: 2018-2019

Loading Chart...
Loading Chart...
2 patents (USPTO):Explore Patents

Title: Marco Feligioni: Innovator in Peptide Systems

Introduction

Marco Feligioni is a notable inventor based in Savona, Italy. He has made significant contributions to the field of peptide systems, particularly in treating diseases associated with glutamate excitotoxicity. With a total of 2 patents to his name, Feligioni's work is paving the way for innovative therapeutic solutions.

Latest Patents

Feligioni's latest patents focus on a cell-permeable peptide system designed to treat diseases caused by glutamate excitotoxicity. The first patent describes a peptide system that includes at least one peptide blocking the presynaptic release of glutamate. The peptide has the sequence SEQ ID NO: GRKKRRQRRRPPIEQSIEQEEGLNRS and/or sequence SEQ ID NO: GRKKRRQRRRPPMSEYNATQSDYRER for use in treating pathologies associated with glutamate excitotoxicity. The second patent reiterates this innovative approach, emphasizing the same sequences for therapeutic applications.

Career Highlights

Throughout his career, Marco Feligioni has demonstrated a commitment to advancing medical science through his inventions. His focus on peptide systems showcases his expertise in biochemistry and pharmacology. Feligioni's work is crucial in addressing the challenges posed by diseases linked to glutamate excitotoxicity.

Collaborations

Feligioni has collaborated with notable individuals in his field, including Robert Giovanni Nistico'. These collaborations have likely contributed to the development and refinement of his innovative peptide systems.

Conclusion

Marco Feligioni stands out as a significant figure in the realm of peptide innovation. His contributions to treating glutamate excitotoxicity highlight the potential of peptide systems in modern medicine. His work continues to inspire advancements in therapeutic solutions.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…